Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

UK. GW Pharmaceuticals clinical trials indicate CBD helps schizophrenia

Dutch Passion

Thursday 17 Sep 2015

GW Pharmaceuticals are probably best known for their Sativex medical cannabis oral spray, a whole-plant extract containing THC and CBD which is licensed for use in Multiple Sclerosis. GW Pharmaceuticals have announced some significant mid-trial success for a CBD-dominant medicine when it was given to a group of Schizophrenia patients. The detailed findings were not released at this stage of the trials, though they will be later. GW said that cannabidiol (CBD) consistently outperformed the placebo, and that the proportion of responders was also higher in the active treatment group. This all suggests that CBD has future uses for treatment of Schizophrenia patients assuming that future medical trials continue to show good results.

Whats more CBD, according to GW Pharma, also showed a very safe profile regarding side effects, something which is particularly welcome in mental-health medicine where some medicines can sometimes have serious side effects.


The full report from GW Pharmaceuticals themselves is here http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Proof%20of%20Concept%20Data%20in%20Sch

http://www.dutch-passion.nl/en/news-and-development/gw-pharmaceuticals-clinical-trials-indicate-CBD-helps-schizophrenia/

 

 

 

After you have finished reading this article you can click here to go back. 




This page was created by the Cannabis Campaigners' Guide.

Feel free to link to this page!